Dairyland Iodine Teat Dip Controlled

Generic Name: iodine liquid

Dosage Form: FOR ANIMAL USE ONLY
Controlled Iodine Teat Dip

TEAT DIPPING is an important part of a MASTITIS CONTROL PLAN:


1. Dip teats immediately after milking.

2. Use good milking and environmental

    management procedures.

3. Use properly functioning milking equipment.

4. Treat every quarter of every cow at dry off.

5. Identify and treat or manage clinical cases

    promptly.

6. Cull chronically infected cows.


GREAT FOR FOAMING

TEAT DIPPING IN COLD WEATHER:

When the temperature falls below 10 degrees F, or when wind chill is significant,

special precautions should be taken to avoid chapped and frozen teats.


1. Teats should be dry before turning cows out into cold weather.

2. When teats are dipped after milking, allow 30 seconds contact, and blot

    off any excess teat dip with a single service towel.

3. Warm the teat dip to reduce drying time.

4. Provide windbreaks in outside areas for cows.

5. Monitor fresh cows with swollen udders and teats since they are more

    susceptible to chapped and frozen teats.

DIRECTIONS FOR USE:


- DO NOT DILUTE.

- Dip teats immediately after milking as a routine part of milking

procedures.

- Dip to THOROUGHLY COVER at least the lower one-third of the teat

(preferably to the base of the udder), IMMEDIATELY after every milking.


TAKE TIME


OBSERVE

LABEL DIRECTIONS


- Empty and clean dip cups after each milking, or during milking, if they

become contaminated.

- Do not pour used dip back into original container.

- KEEP FROM FREEZING

- Keep container closed to prevent contamination.

- Store container in an upright position.


FIRST-AID

EYES: If contact with eyes occurs, flush with plenty of cool water for 15

minutes. Consult a physician.

INTERNAL: May be harmful if swallowed. If ingested, drink large amounts of

water or milk. DO NOT induce vomiting. Get medical attention immediately.


FOR ASSISTANCE WITH MEDICAL

EMERGENCY CONTACT:

CHEM-TEL, 1-800-255-3924


DAIRYLAND BRAND

Controlled

Iodine Teat Dip

A SANITIZING TEAT DIP

An Aid in Reducing the Spread of

Organisms Which May Cause Mastitis

ACTIVE INGREDIENTS:

Concentrated Iodophor, containing Nonylphenol, ethoxylated iodine complex.

(provides 1/2% titratable iodine, equivalent to 5,000 ppm titratable iodine)

Emollient system contains 4.50% glycerine and 0.06% lanolin.

KEEP OUT OF THE REACH OF CHILDREN - CAUTION:

HARMFUL IF SWALLOWED / EYE IRRITANT

STEARNS PACKAGING CORPORATION

4200 Sycamore Avenue - Madison, Wisconsin  53714

NET CONTENTS:  1 U.S. FL. GALLON (3.78 LITERS)

DAIRYLAND BRAND IODINE TEAT DIP  CONTROLLED iodine  liquid

Product Information Product Type OTC ANIMAL DRUG NDC Product Code (Source) 60282-2200 Route of Administration TOPICAL DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength IODINE (IODINE) IODINE 0.5 L  in 100 L

Inactive Ingredients Ingredient Name Strength GLYCERIN 4.5 L  in 100 L LANOLIN 0.06 L  in 100 L

Product Characteristics Color      Score      Shape Size Flavor Imprint Code Contains

Packaging # NDC Package Description Multilevel Packaging 1 60282-2200-1 3.78 L In 1 BOTTLE, PLASTIC None 2 60282-2200-2 18.93 L In 1 PAIL None 3 60282-2200-3 56.78 L In 1 DRUM None 4 60282-2200-4 208.2 L In 1 DRUM None

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved drug other		01/02/1982

Labeler - Stearns Packaging Corporation (006069256)

Registrant - Stearns Packaging Corporation (006069256)

Establishment
Name	Address	ID/FEI	Operations
Stearns Packaging Corporation		006069256	manufacture

Revised: 09/2010Stearns Packaging Corporation

Ramelteon

Class: Anxiolytics, Sedatives, and Hypnotics; Miscellaneous
VA Class: CN300
Chemical Name: N-[2-[8S)-1,6,7,8-Tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl-propanamide
Molecular Formula: C₁₆H₂₁NO₂
CAS Number: 196597-26-9
Brands: Rozerem

REMS:

FDA approved a REMS for ramelteon to ensure that the benefits of a drug outweigh the risks. However, FDA later rescinded REMS requirements. See the FDA REMS page () or the ASHP REMS Resource Center ().

Introduction

Melatonin receptor agonist; hypnotic.^{1 2}

Uses for Ramelteon

Insomnia

Management of insomnia characterized by difficulty with sleep onset.¹

Decreases sleep latency in patients with transient insomnia.^{1 2} Decreases sleep latency in patients with chronic insomnia receiving therapy for up to 35 days.^{1 2 3 4 5}

Ramelteon Dosage and Administration

Administration

Oral Administration

Administer orally within 30 minutes of bedtime.^{1 2}

Avoid administration with or immediately after a high-fat meal because of potentially decreased rate of absorption.^{1 2} (See Food under Pharmacokinetics.)

Dosage

Adults

Insomnia

Oral

8 mg.^{1 2}

Special Populations

Hepatic Impairment

Increased exposure to drug and active metabolite.¹ (See Special Populations under Pharmacokinetics.) No specific dosage recommendations at this time.¹ However, use with caution in patients with moderate hepatic impairment; avoid use in patients with severe hepatic impairment.¹

Renal Impairment

No dosage adjustment necessary in patients with mild, moderate, or severe renal impairment or in those requiring chronic hemodialysis.¹

Cautions for Ramelteon

Contraindications

• 
  

  Hypersensitivity to ramelteon or any ingredient in the formulation.¹

  
  

Warnings/Precautions

Warnings

Adequate Patient Evaluation

Sleep disturbances may be a manifestation of a physical and/or psychiatric disorder; carefully evaluate patient before providing symptomatic treatment.¹

Failure of insomnia to remit after a reasonable treatment period, exacerbation of insomnia, and/or emergence of new cognitive or behavioral abnormalities may indicate the presence of an underlying psychiatric or physical disorder requiring further patient evaluation.¹

Complex Sleep-related Behaviors

Potential risk of complex sleep-related behaviors such as sleep-driving (i.e., driving while not fully awake after ingesting a sedative-hypnotic drug, with no memory of the event), making phone calls, or preparing and eating food while asleep.⁶

Sensitivity Reactions

Potential risk of anaphylaxis and angioedema; may occur as early as with the first dose of drug.⁶

Major Toxicities

Psychiatric Effects

Cognitive and behavioral changes reported.¹ In primarily depressed patients, exacerbation of depression and suicidal ideation reported following use of hypnotics.¹

Immediately evaluate any new psychiatric abnormalities.¹

Endocrine Effects

Increased prolactin concentrations reported in patients with chronic insomnia receiving ramelteon 16 mg daily for 6 months.¹

Abnormal morning cortisol concentrations (resulting in abnormal corticotropin [ACTH] stimulation test results) reported in 2 patients and prolactinoma reported in 1 patient receiving long-term (up to 12 months) therapy; causal relationship to drug not established.¹

If unexplained amenorrhea, galactorrhea, decreased libido, or fertility problems occur, consider evaluating prolactin or testosterone concentrations.¹

Abuse Potential and Dependence

No evidence of abuse potential detected following administration of doses up to 20 times the recommended hypnotic dose in patients with a history of drug abuse or dependence.^{1 2}

No evidence of physical dependence.¹

Withdrawal

No evidence of a withdrawal syndrome, including rebound insomnia, following discontinuance of long-term therapy (4, 8, or 16 mg daily for up to 35 days).^{1 2}

Residual Effects

Next-day residual effects (reduced immediate/delayed memory recall and increased sluggishness, fatigue, and irritation) detected at weeks 1 and 3 but not week 5 of therapy in adult patients receiving ramelteon 8 mg daily.^{1 2} Residual effects not detected in a similar study in geriatric patients receiving ramelteon 4 or 8 mg daily.^{1 2}

General Precautions

Long-term Safety

No clinically meaningful changes in laboratory parameters, endocrine tests, vital signs, ECG recordings, or intensity of menstrual bleeding detected in patients with chronic insomnia following up to 1 year of therapy.² Rebound insomnia not observed following 1 year of therapy.²

Concomitant Diseases

No respiratory depressant effect in patients with mild to moderate COPD.¹ Effects in patients with severe COPD (e.g., those with elevated pCO₂, those requiring nocturnal oxygen therapy) not studied; use in these patients not recommended.¹

No differences in measures of apnea indices observed in patients with mild to moderate obstructive sleep apnea.¹ Effects in patients with severe obstructive sleep apnea not studied; use in these patients not recommended.¹

Specific Populations

Pregnancy

Category C.¹

Lactation

Distributed into milk in rats; not known whether distributed into human milk.¹ Use not recommended.¹

Pediatric Use

Safety and efficacy not established in pediatric patients.¹

Geriatric Use

Increased exposure to drug and active metabolite.¹ (See Special Populations under Pharmacokinetics.) However, no overall differences in safety or efficacy relative to younger adults.¹

Hepatic Impairment

Use with caution in patients with moderate hepatic impairment; avoid use in patients with severe hepatic impairment.¹ (See Special Populations under Pharmacokinetics.)

Common Adverse Effects

Headache, somnolence, dizziness, fatigue, nausea, exacerbation of insomnia, upper respiratory tract infection, diarrhea, myalgia, depression, dysgeusia, arthralgia.¹

Interactions for Ramelteon

Metabolized principally by CYP1A2 and, to a lesser extent, by the CYP2C subfamily and by CYP3A4.¹

Drugs Affecting Hepatic Microsomal Enzymes

Inhibitors of CYP1A2: Potential pharmacokinetic interaction (substantially increased serum ramelteon concentrations).¹ Avoid concomitant use with strong CYP1A2 inhibitors; caution if used concomitantly with less potent CYP1A2 inhibitors.¹

Inhibitors of CYP3A4 and CYP2C9: Potential pharmacokinetic interaction (increased serum concentrations of ramelteon and active metabolite).¹ Caution if used concomitantly with potent inhibitors of CYP3A4 or CYP2C9.¹

Inducers of CYP isoenzymes: Potential pharmacokinetic interaction (decreased serum concentrations of ramelteon and active metabolite).¹ Possibly reduced ramelteon efficacy when used concomitantly with potent CYP inducers.^{1 2}

Drugs Metabolized by Hepatic Microsomal Enzymes

Substrates of CYP isoenzymes 1A2, 2C9, 2C19, 2D6, and 3A4: Pharmacokinetic interaction unlikely.¹

Specific Drugs

Drug or Test	Interaction	Comments
Alcohol	Additive sedative effects1	Avoid concomitant use1
Dextromethorphan	Pharmacokinetic interaction unlikely1
Digoxin	Pharmacokinetic interaction unlikely1
Fluconazole	Increased peak serum concentrations and AUC of ramelteon and active metabolite1	Use concomitantly with caution1
Fluoxetine	Pharmacokinetic interaction unlikely1
Fluvoxamine	Substantially increased peak serum concentration and AUC of ramelteon1	Avoid concomitant use1
Ketoconazole	Increased peak serum concentration and AUC of ramelteon and active metabolite1	Use concomitantly with caution1
Midazolam	Pharmacokinetic interaction unlikely1
Omeprazole	Pharmacokinetic interaction unlikely1
Rifampin	Decreased peak serum concentration and AUC of ramelteon and active metabolite1	Concomitant use may reduce efficacy of ramelteon1 2
Theophylline	Pharmacokinetic interaction unlikely1
Warfarin	Pharmacokinetic interaction unlikely1
Urine Drug Screening	No false-positive results for urine drug screening of benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines1

Ramelteon Pharmacokinetics

Absorption

Bioavailability

Rapidly absorbed; following oral administration in fasting state, peak serum concentrations occur at approximately 0.75 hour.¹

Total absorption is ≥84%; however, absolute oral bioavailability is 1.8% because of extensive first-pass metabolism.¹

Food

High-fat meal delays time to peak serum concentration by 45 minutes, reduces peak serum concentration by 22%, and increases AUC by 31%.¹ (See Oral Administration under Dosage and Administration.)

Special Populations

In geriatric patients, peak serum concentrations and AUC of ramelteon are increased by 86 and 97%, respectively.¹ Peak serum concentrations and AUC of active metabolite also are increased, but to a lesser extent.¹

In patients with mild or moderate hepatic impairment, exposure to ramelteon is increased 4- or 10-fold, respectively.¹ Exposure to active metabolite is marginally increased.¹ Pharmacokinetic parameters not evaluated in patients with severe hepatic impairment (Child-Pugh class C).¹ (See Hepatic Impairment under Cautions.)

Pharmacokinetic parameters not altered in patients with renal impairment or in those requiring chronic hemodialysis.¹

Distribution

Extent

Extensively distributed into tissues; not distributed selectively to red blood cells.¹

Plasma Protein Binding

Approximately 82% (mainly [70%] albumin).¹

Elimination

Metabolism

Metabolized principally by CYP1A2 and, to a lesser extent, by the CYP2C subfamily and by CYP3A4 to active (M-II) and inactive metabolites.¹

Elimination Route

Excreted in urine (84%) and feces (4%), principally as metabolites.¹

Half-life

1–2.6 hours (for ramelteon) and 2–5 hours (for active metabolite).¹

Stability

Storage

Oral

Capsules

Tightly-closed containers at 25°C (may be exposed to 15–30°C).¹ Protect from moisture and humidity.¹

Actions

• 
  

  Exhibits high affinity for melatonin MT₁ and MT₂ receptors.^{1 2} Agonist activity at these receptors may contribute to the drug’s sleep-inducing properties.^{1 2}

  
  


• 
  

  Demonstrates lower selectivity for melatonin MT₃ receptors than for MT₁ and MT₂ receptors.¹ Has no appreciable affinity for the GABA receptor complex or for receptors that bind neuropeptides, cytokines, serotonin, dopamine, norepinephrine, acetylcholine, or opiates.¹

  
  

Advice to Patients

• 
  

  Necessity of administering within 30 minutes of bedtime and limiting activities to only those necessary to prepare for bed.¹ Avoid administration with or immediately after a high-fat meal.¹

  
  


• 
  

  Necessity of avoiding driving, operating machinery, or performing hazardous tasks following administration.¹ Importance of avoiding alcohol during therapy.¹

  
  


• 
  

  Importance of consulting a clinician if worsening insomnia or emergence of new behavioral manifestations occurs.¹

  
  


• 
  

  Importance of consulting a clinician if cessation of menses or galactorrhea (in women), decreased libido, or problems with fertility occur.¹

  
  


• 
  

  Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.¹

  
  


• 
  

  Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.¹

  
  


• 
  

  Importance of informing patients of other important precautionary information.¹ (See Cautions.)

  
  

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Ramelteon

Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Oral	Tablets, film-coated	8 mg	Rozerem	Takeda

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 10/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Rozerem 8MG Tablets (TAKEDA PHARMACEUTICALS): 30/$171.00 or 90/$472.99

Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions October 27, 2011. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

References

1. Takeda Pharmaceuticals America, Inc. Rozerem (ramelteon) tablets prescribing information. Lincolnshire, IL; 2005 Aug.

2. Takeda Pharmaceuticals America, Inc., Lincolnshire, IL: Personal communication.

3. Zammit G, Roth T, Erman M et al. Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia. Sleep. 2005; 28(Suppl):A228-9.

4. Roth T, Seiden D, Weigand S et al. Phase III study to determine the efficacy of ramelteon in elderly patients with chronic insomnia. Proceedings of New Clinical Drug Evaluation Unit. June 6-9, 2005, Boca Raton, Fla. Poster abstract.

5. Roth T, Seiden D, Zee P et al. Phase III outpatient trial of ramelteon for the treatment of chronic insomnia in elderly patients. J Am Geriatr Soc. 2005; 53(Suppl):S25. Abstract.

6. Food and Drug Administration. Rozerem (ramelteon) tablets. [March 14, 2007: Takeda] MedWatch drug labeling changes. Rockville, MD; April 2007. From FDA websites () and ().

More Ramelteon resources

• Ramelteon Side Effects (in more detail)
• Ramelteon Use in Pregnancy & Breastfeeding
• Ramelteon Drug Interactions
• Ramelteon Support Group
• 29 Reviews for Ramelteon - Add your own review/rating

• Ramelteon MedFacts Consumer Leaflet (Wolters Kluwer)


• Ramelteon Professional Patient Advice (Wolters Kluwer)


• ramelteon Advanced Consumer (Micromedex) - Includes Dosage Information


• Rozerem Prescribing Information (FDA)


• Rozerem Consumer Overview

Compare Ramelteon with other medications

• Insomnia

RabAvert (obsolete)

Generic Name: rabies vaccine (ray BEES vack seen)

Brand Names: Imovax Rabies (obsolete), Imovax Rabies I.D. (obsolete), RabAvert (obsolete), Rabies Vaccine (obsolete)

What is RabAvert (obsolete) (rabies vaccine)?

Rabies is a serious disease caused by a virus. Rabies is mainly a disease of animals. Humans get rabies when they are bitten by an infected animal. There may be no symptoms at first, but weeks or even years after a bite from an infected animal, rabies can cause pain, fatigue, headaches, irritability, fever, seizures, hallucinations, and paralysis. Rabies can be fatal.

What is the most important information I should know about RabAvert (obsolete) (rabies vaccine)?

People with minor illnesses, such as a cold, may be vaccinated. Those who are moderately or severely ill should usually wait until they recover before getting rabies vaccine. However, if you have been exposed to the rabies virus, you should get the vaccine regardless of any other illnesses you may have.

What should I discuss with my healthcare provider before receiving RabAvert (obsolete) (rabies vaccine)?

Tell your doctor if you have had a life-threatening allergic reaction to the rabies vaccine or a component of the vaccine.

People at high risk of exposure to rabies include veterinarians, animal handlers, rabies laboratory workers, spelunkers, rabies biologics production workers, or anyone who is likely to come in contact with infected animals or the virus itself. These people should be offered rabies vaccine.

Before receiving rabies vaccine, talk to your doctor if you:

• 
  

  have HIV or AIDS or another disease that affects the immune system;

  
  


• 
  

  are taking an antimalarial drug;

  
  


• 
  

  are taking a medication that affects the immune system (e.g. steroids, anti-rejection medications);

  
  


• 
  

  have cancer; or

  
  


• 
  

  are receiving cancer treatment with x-rays, radiation, or medication.

  
  

Ask your healthcare provider for more information. Rabies vaccine may not be recommended in some cases.

People with minor illnesses, such as a cold, may be vaccinated. Those who are moderately or severely ill should usually wait until they recover before getting rabies vaccine. However, if you have been exposed to the rabies virus, you should get the vaccine regardless of any other illnesses you may have.

Talk to your doctor before receiving rabies vaccine if you are pregnant or breast-feeding a baby.

How is rabies vaccine administered?

Your doctor, nurse, or other healthcare provider will administer the rabies vaccine as an injection.

What happens if I miss a dose?

Talk to your doctor if you miss a dose.

What happens if I overdose?

An overdose of rabies vaccine is unlikely to occur.

What should I avoid before or after getting RabAvert (obsolete) (rabies vaccine)?

There are no restrictions on food, beverages, or activity before or after receiving rabies vaccine.

RabAvert (obsolete) (rabies vaccine) side effects

Getting rabies disease is much riskier than getting rabies vaccine. However, a vaccine, like any medicine, is capable of causing serious problems, such as severe allergic reactions. The risk of rabies vaccine causing serious harm, or death, is extremely small.

Seek emergency medical attention or contact your doctor immediately if any of the following rare but serious side effects from rabies vaccine are experienced:

• 
  

  a serious allergic reaction including swelling of the lips, tongue, or face; difficulty breathing; closing of the throat; hives; paleness; weakness; dizziness; or a fast heart beat within a few minutes to a few hours after the shot;

  
  


• 
  

  high fever; or

  
  


• 
  

  behavior changes.

  
  

Some people who get rabies vaccine get a sore spot where the shot was given.

Side effects other than those listed here may also occur. Contact your doctor about any side effect that seems unusual or that is especially bothersome.

What other drugs will affect RabAvert (obsolete) (rabies vaccine)?

Talk to your doctor before receiving rabies vaccine if you are taking any of the following medications that may affect the immune system:

• 
  

  an oral or injectable steroid medication such as betamethasone (Celestone), cortisone (Cortone), dexamethasone (Decadron, Dexone), hydrocortisone (Cortef, Hydrocortone), methylprednisolone (Medrol), prednisolone (Prelone, Pediapred), prednisone (Orasone, Deltasone, others), or triamcinolone (Aristocort);

  
  


• 
  

  an inhaled or nasal steroid such as beclomethasone (Qvar, Beclovent, Beconase, Vanceril, Vancenase), budesonide (Pulmicort, Rhinocort), flunisolide (Aerobid, Nasalide, Nasarel), fluticasone (Flovent, Flonase), mometasone (Nasonex), or triamcinolone (Azmacort, Nasacort);

  
  


• 
  

  treatment for cancer with chemotherapy (medication), radiation, or x-rays;

  
  


• 
  

  azathioprine (Imuran);

  
  


• 
  

  basiliximab (Simulect);

  
  


• 
  

  cyclosporine (Sandimmune, Neoral, Gengraf);

  
  


• 
  

  etanercept (Enbrel);

  
  


• 
  

  leflunomide (Arava);

  
  


• 
  

  muromonab-CD3 (Orthoclone);

  
  


• 
  

  mycophenolate mofetil (CellCept);

  
  


• 
  

  sirolimus (Rapamune); or

  
  


• 
  

  tacrolimus (Prograf).

  
  

Other drugs may affect rabies vaccine, talk to your doctor about any medications you are taking.

Where can I get more information?

• Your doctor or pharmacist may have additional information or suggest additional resources regarding rabies vaccine.

Maxipime

Maxipime is a brand name of cefepime, approved by the FDA in the following formulation(s):

MAXIPIME (cefepime hydrochloride - injectable; injection)

• 
  Manufacturer: HOSPIRA INC
  
  Approval date: January 18, 1996
  
  Strength(s): EQ 1GM BASE/VIAL ^[RLD][AP], EQ 2GM BASE/VIAL ^[RLD][AP], EQ 500MG BASE/VIAL ^[RLD][AP]

Has a generic version of Maxipime been approved?

Yes. The following products are equivalent to Maxipime:

cefepime hydrochloride injectable; injection

• 
  Manufacturer: ACS DOBFAR
  
  Approval date: March 20, 2008
  
  Strength(s): EQ 1GM BASE/VIAL ^[AP], EQ 2GM BASE/VIAL ^[AP]


• 
  Manufacturer: SANDOZ
  
  Approval date: December 21, 2010
  
  Strength(s): EQ 1GM BASE/VIAL ^[AP], EQ 2GM BASE/VIAL ^[AP], EQ 500MG BASE/VIAL ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Maxipime. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Maxipime.

See also...

• Maxipime Consumer Information (Wolters Kluwer)
• Maxipime Consumer Information (Cerner Multum)
• Maxipime ADD-Vantage Consumer Information (Cerner Multum)
• Maxipime Advanced Consumer Information (Micromedex)
• Maxipime AHFS DI Monographs (ASHP)
• Cefepime Consumer Information (Wolters Kluwer)
• Cefepime Consumer Information (Cerner Multum)
• Cefepime Injection Advanced Consumer Information (Micromedex)
• Cefepime Hydrochloride AHFS DI Monographs (ASHP)

Doxycycline Monohydrate Capsules and Omega-3/Vitamin E

Pronunciation: DOX-i-SYE-kleen/oh-MAY-ga 3/VYE-ta-min E
Generic Name: Doxycycline Monohydrate Capsules and Omega-3/Vitamin E
Brand Name: Nutridox Convenience Kit

Doxycycline Monohydrate Capsules and Omega-3/Vitamin E is used for:

Treating certain bacterial infections of the eye. It may also be used to treat certain other bacterial infections or to prevent or slow the progression of anthrax after exposure.

Doxycycline Monohydrate Capsules and Omega-3/Vitamin E is a kit which contains a tetracycline antibiotic and omega-3/vitamin E capsule. The antibiotic works by slowing the growth of bacteria. Slowing the bacteria's growth allows the body's immune system to destroy the bacteria. The omega-3/vitamin E capsule works to improve tear production, which protects and moisturizes the eye.

Do NOT use Doxycycline Monohydrate Capsules and Omega-3/Vitamin E if:

• you are allergic to any ingredient in Doxycycline Monohydrate Capsules and Omega-3/Vitamin E or to another tetracycline (eg, minocycline)


• you are taking acitretin, isotretinoin, or a penicillin (eg, amoxicillin)


• you have recently received or will be receiving a live oral typhoid vaccine

Contact your doctor or health care provider right away if any of these apply to you.

Before using Doxycycline Monohydrate Capsules and Omega-3/Vitamin E:

Some medical conditions may interact with Doxycycline Monohydrate Capsules and Omega-3/Vitamin E. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have diarrhea, a history of lupus, or the blood disease porphyria

Some MEDICINES MAY INTERACT with Doxycycline Monohydrate Capsules and Omega-3/Vitamin E. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Barbiturates (eg, phenobarbital), carbamazepine, hydantoins (eg, phenytoin), iron, or urinary alkalinizers (eg, sodium bicarbonate) because they may decrease Doxycycline Monohydrate Capsules and Omega-3/Vitamin E's effectiveness


• Acitretin, anticoagulants (eg, warfarin), digoxin, isotretinoin, methotrexate, or methoxyflurane because the risk of their side effects may be increased by Doxycycline Monohydrate Capsules and Omega-3/Vitamin E


• Hormonal birth control (eg, birth control pills), live oral typhoid vaccine, or penicillins (eg, amoxicillin) because their effectiveness may be decreased by Doxycycline Monohydrate Capsules and Omega-3/Vitamin E

This may not be a complete list of all interactions that may occur. Ask your health care provider if Doxycycline Monohydrate Capsules and Omega-3/Vitamin E may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Doxycycline Monohydrate Capsules and Omega-3/Vitamin E:

Use Doxycycline Monohydrate Capsules and Omega-3/Vitamin E as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• For the doxycycline capsules: Take Doxycycline Monohydrate Capsules and Omega-3/Vitamin E by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.


• Do not take an antacid that has aluminum, calcium, or magnesium in it; bismuth-containing products; iron; urinary alkalinizers (eg, sodium bicarbonate); or multivitamins with minerals within 2 hours before or 2 hours after you take Doxycycline Monohydrate Capsules and Omega-3/Vitamin E.


• To clear up your infection completely, take Doxycycline Monohydrate Capsules and Omega-3/Vitamin E for the full course of treatment. Keep taking it even if you feel better in a few days.


• Drink plenty of fluids with Doxycycline Monohydrate Capsules and Omega-3/Vitamin E to wash it down and avoid the risk of throat irritation.


• Do not use Doxycycline Monohydrate Capsules and Omega-3/Vitamin E if it is out of date or has been stored incorrectly.


• For the omega-3/vitamin E capsules: Take Doxycycline Monohydrate Capsules and Omega-3/Vitamin E by mouth with or without food.


• If you miss a dose of Doxycycline Monohydrate Capsules and Omega-3/Vitamin E, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Doxycycline Monohydrate Capsules and Omega-3/Vitamin E.

Important safety information:

• Be sure to use Doxycycline Monohydrate Capsules and Omega-3/Vitamin E for the full course of treatment. If you do not, the medicine may not clear up your infection completely. The bacteria could also become less sensitive to this or other medicines. This could make the infection harder to treat in the future.


• Doxycycline Monohydrate Capsules and Omega-3/Vitamin E only works against bacteria; it does not treat viral infections (eg, the common cold).


• Long-term or repeated use of Doxycycline Monohydrate Capsules and Omega-3/Vitamin E may cause a second infection. Tell your doctor if signs of a second infection occur. Your medicine may need to be changed to treat this.


• Hormonal birth control (eg, birth control pills) may not work as well while you are using Doxycycline Monohydrate Capsules and Omega-3/Vitamin E. To prevent pregnancy, use an extra form of birth control (eg, condoms).


• Doxycycline Monohydrate Capsules and Omega-3/Vitamin E may cause you to become sunburned more easily. Avoid the sun, sunlamps, or tanning booths until you know how you react to Doxycycline Monohydrate Capsules and Omega-3/Vitamin E. Use a sunscreen or wear protective clothing if you must be outside for more than a short time.


• Mild diarrhea is common with antibiotic use. However, a more serious form of diarrhea (pseudomembranous colitis) may rarely occur. This may develop while you use the antibiotic or within several months after you stop using it. Contact your doctor right away if stomach pain or cramps, severe diarrhea, or bloody stools occur. Do not treat diarrhea without first checking with your doctor.


• Do NOT take more than the recommended dose or use for longer than prescribed without checking with your doctor.


• Tell your doctor or dentist that you take Doxycycline Monohydrate Capsules and Omega-3/Vitamin E before you receive any medical or dental care, emergency care, or surgery.


• Doxycycline Monohydrate Capsules and Omega-3/Vitamin E may interfere with certain lab tests. Be sure your doctor and lab personnel know you are taking Doxycycline Monohydrate Capsules and Omega-3/Vitamin E.


• Lab tests, including liver function, kidney function, and complete blood cell counts, may be performed while you use Doxycycline Monohydrate Capsules and Omega-3/Vitamin E. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.


• Use Doxycycline Monohydrate Capsules and Omega-3/Vitamin E with extreme caution in CHILDREN younger than 10 years old who have diarrhea or an infection of the stomach or bowel.


• Doxycycline Monohydrate Capsules and Omega-3/Vitamin E should not be used in CHILDREN younger than 8 years old; permanent yellow-gray-brown tooth discoloration may occur.


• PREGNANCY and BREAST-FEEDING: Doxycycline Monohydrate Capsules and Omega-3/Vitamin E has been shown to cause harm to the fetus. If you think you may be pregnant, contact your doctor. You will need to discuss the benefits and risks of using Doxycycline Monohydrate Capsules and Omega-3/Vitamin E while you are pregnant. Doxycycline Monohydrate Capsules and Omega-3/Vitamin E is found in breast milk. Do not breast-feed while taking Doxycycline Monohydrate Capsules and Omega-3/Vitamin E.

Possible side effects of Doxycycline Monohydrate Capsules and Omega-3/Vitamin E:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Loss of appetite; mild diarrhea; nausea; vomiting.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); bloody stools; chest pain; dark urine; decreased urination; fever, chills, or sore throat; moderate to severe sunburn; red, swollen, blistered, or peeling skin; severe diarrhea; severe or persistent headache; stomach pain or cramps; throat irritation; trouble swallowing; unusual bruising or bleeding; unusual joint pain; unusual tiredness; vaginal irritation or discharge; vision changes; yellowing of the skin or eyes.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.

Proper storage of Doxycycline Monohydrate Capsules and Omega-3/Vitamin E:

Store Doxycycline Monohydrate Capsules and Omega-3/Vitamin E at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Doxycycline Monohydrate Capsules and Omega-3/Vitamin E out of the reach of children and away from pets.

General information:

• If you have any questions about Doxycycline Monohydrate Capsules and Omega-3/Vitamin E, please talk with your doctor, pharmacist, or other health care provider.


• Doxycycline Monohydrate Capsules and Omega-3/Vitamin E is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Doxycycline Monohydrate Capsules and Omega-3/Vitamin E. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Doxycycline Monohydrate Capsules and Omega-3/Vitamin E resources

• Doxycycline Monohydrate Capsules and Omega-3/Vitamin E Use in Pregnancy & Breastfeeding
• Doxycycline Monohydrate Capsules and Omega-3/Vitamin E Drug Interactions
• Doxycycline Monohydrate Capsules and Omega-3/Vitamin E Support Group
• 0 Reviews · Be the first to review/rate this drug

Loperamide Zydus

Loperamide Zydus may be available in the countries listed below.

Ingredient matches for Loperamide Zydus

Loperamide

Loperamide hydrochloride (a derivative of Loperamide) is reported as an ingredient of Loperamide Zydus in the following countries:

• France

International Drug Name Search

Barbloc

Barbloc may be available in the countries listed below.

Ingredient matches for Barbloc

Pindolol

Pindolol is reported as an ingredient of Barbloc in the following countries:

• Australia


• Taiwan

International Drug Name Search